GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19-SUBUNIT MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE BIOLOGIC-NAIVE OR PRIOR TNFα INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

被引：0

作者：

Deodhar, Atul ^{[1
]}

Helliwell, Philip ^{[2
]}

Boencke, Wolf-Henning ^{[3
]}

Hsia, Elizabeth C. ^{[4
,5
,6
]}

Kollmeier, Alexa P. ^{[4
,5
]}

Subramanian, Ramanand A. ^{[4
,5
]}

Xu, Xie L. ^{[4
,5
]}

Sheng, Shihong ^{[4
,5
]}

Zhou, Bei ^{[4
,5
]}

Zazzetti, Federico ^{[7
]}

Ritchlin, Christopher ^{[8
]}

机构：

[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[2] Univ Leeds, Leeds, W Yorkshire, England

[3] Geneva Univ Hosp, Geneva, Switzerland

[4] Janssen Res & Dev LLC, Spring House, PA USA

[5] Janssen Res & Dev LLC, San Diego, CA USA

[6] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA

[7] Janssen LATAM Med Affairs, Buenos Aires, DF, Argentina

[8] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

298

引用

页码：24 / 24

页数：1

共 50 条

[1] Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naive or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Deodhar, Atul
Helliwell, Philip
Boencke, Wolf-Henning
Hsia, Elizabeth
Kollmeier, Alexa
Subramanian, Ramanand
Xu, Xie
Sheng, Shihong
Zhou, Bei
Ritchlin, Christopher
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[2] GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSA WHO WERE BIOLOGIC-NAIVE OR PRIOR TNFα INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Deodhar, Atul
Helliwell, Philip
Boehncke, Wolf-Henning
Hsia, Elizabeth C.
Kollmeier, Alexa P.
Subramanian, Ramanand A.
Xu, Xie L.
Sheng, Shihong
Zhou, Bei
Gorecki, Patricia C.
Ritchlin, Christopher
RHEUMATOLOGY, 2020, 59
[3] GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 24 RESULTS OF THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Mease, Philip J.
Rahman, Proton
Gottlieb, Alice
Hsia, Elizabeth
Kollmeier, Alexa P.
Xu, Xie L.
Subramanian, Ramanand A.
Agarwal, Prasheen
Sheng, Shihong
Zhou, Bei
van der Helide, Desiree
Zazzetti, Federico
McInnes, Lin B.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 23 - 23
[4] Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naive Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Mease, Philip J.
Rahman, Proton
Gottlieb, Alice B.
Hsia, Elizabeth
Kollmeier, Alexa
Xu, Xie
Subramanian, Ramanand
Agarwal, Prasheen
Sheng, Shihong
Zhou, Bei
van der Heijde, Desiree
McInnes, Iain
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[5] Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through Week 52 of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
McInnes, Iain
Rahman, Proton
Gottlieb, Alice
Hsia, Elizabeth
Kollmeier, Alexa
Xu, Xie
Subramanian, Ramanand
Agarwal, Prasheen
Sheng, Shihong
Jiang, Yusang
Zhou, Bei
van der Heijde, Desiree
Mease, Philip
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[6] EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBUNIT OF INTERLEUKIN-23, THROUGH WEEK 52 OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mcinnes, I.
Rahman, P.
Gottlieb, A. B.
Hsia, E. C.
Kollmeier, A.
Xu, X. L.
Subramanian, R. A.
Agarwal, P.
Sheng, S.
Jiang, Y.
Zhou, B.
Van der Heijde, D.
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1148 - 1149
[7] Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naive or TNFα Inhibitor-Experienced
Ritchlin, Christopher
Helliwell, Philip
Boehncke, Wolf-Henning
Hsia, Elizabeth
Kollmeier, Alexa
Subramanian, Ramanand
Xu, Xie
Sheng, Shihong
Jiang, Yusang
Zhou, Bei
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[8] GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAIVE OR TNF-A INHIBITOR-EXPERIENCED
Ritchlin, C. T.
Helliwell, P.
Boehncke, W. H.
Hsia, E. C.
Kollmeier, A.
Subramanian, R. A.
Xu, X. L.
Sheng, S.
Jiang, Y.
Zhou, B.
Deodhar, A.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1144 - 1145
[9] EFFICACY AND SAFETYOF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE P19-SUBITNIT OF INTERLEUKIN-23, THROUGH WEEK 5201 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Ranza, Roberto
McInnes, Iain B.
Rahman, Proton
Gottlieb, Alice B.
Hsia, Elizabeth C.
Kollmeier, Alexa P.
Xu, Xie L.
Subramanian, Ramanand A.
Agarwal, Prasheen
Sheng, Shihong
Jiang, Yusang
Zhou, Bei
Van der Heijde, Desiree
Mease, Philip J.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S111 - S111
[10] EFFICACY AND SAFETY OF GUSELKUMAB, A MONOCLONAL ANTIBODY SPECIFIC TO THE p19-SUBUNIT OF INTERLEUKIN-23, THROUGH 2 YEARS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Mcinnes, I.
Rahman, P.
Gottlieb, A. B.
Hsia, E. C.
Kollmeier, A.
Xu, X. L.
Sheng, S.
Jiang, Y.
Shawi, M.
Chakravarty, S. D.
Van der Heijde, D.
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 783 - 784

← 1 2 3 4 5 →